Get the Stockscreener App
18.59
1.17%
-0.22
Pre-market:
19.06
0.47
+2.53%
Takeda Pharmaceutical Co Adr stock is traded at $18.59, with a volume of 3.26M.
It is down -1.17% in the last 24 hours and up +1.92% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
See More
Previous Close:
$18.81
Open:
$18.55
24h Volume:
3.26M
Relative Volume:
1.07
Market Cap:
$59.37B
Revenue:
$29.91B
Net Income/Loss:
$1.30B
P/E Ratio:
45.83
EPS:
0.4056
Net Cash Flow:
$3.49B
1W Performance:
-2.41%
1M Performance:
+1.92%
6M Performance:
+3.05%
1Y Performance:
+24.26%
1-Day Range:
$18.51
$18.73
1-Week Range:
$18.51
$19.05
52-Week Range:
$12.99
$19.10
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
472.21 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-13-26 | Resumed | Morgan Stanley | Overweight |
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr Reddy's Laboratories stock gains attention on QDENGA vaccine deal - AD HOC NEWS
NY stocks mixed, Dow falls for first time in 3 days on rate hike concerns - finance.biggo.com
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
SGIOY Stock Price, Quote & News - Syfe
Protagonist Therapeutics receives FDA approval for polycythemia vera drug By Investing.com - Investing.com India
Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - valueresearchonline.com
Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed ToneBlock Trade Flow - vinanet.vn
Corporate Lobbying Dashboard - Quiver Quantitative
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Earnings call transcript: Takeda Q1 2026 results show steady growth, stock slips premarket - Investing.com
Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance LevelBPI Bull Correction - vinanet.vn
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
6 High-Yield International Dividend Stocks Analysts Love - Forbes
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - grandviewresearch.com
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
TAK/N Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (GETTEX:TKDA) - TradingView
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.10%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):